BR112022016661A2 - Receptores de células t restritos ao hla classe ii contra ras com mutação g12v - Google Patents

Receptores de células t restritos ao hla classe ii contra ras com mutação g12v

Info

Publication number
BR112022016661A2
BR112022016661A2 BR112022016661A BR112022016661A BR112022016661A2 BR 112022016661 A2 BR112022016661 A2 BR 112022016661A2 BR 112022016661 A BR112022016661 A BR 112022016661A BR 112022016661 A BR112022016661 A BR 112022016661A BR 112022016661 A2 BR112022016661 A2 BR 112022016661A2
Authority
BR
Brazil
Prior art keywords
cell receptors
mutation
restricted
hla class
relates
Prior art date
Application number
BR112022016661A
Other languages
English (en)
Portuguese (pt)
Inventor
Levin Noam
Yoseph Rami
C Paria Biman
A Rosenberg Steven
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of BR112022016661A2 publication Critical patent/BR112022016661A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
BR112022016661A 2020-02-26 2021-02-26 Receptores de células t restritos ao hla classe ii contra ras com mutação g12v BR112022016661A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062981856P 2020-02-26 2020-02-26
PCT/US2021/019775 WO2021173902A1 (en) 2020-02-26 2021-02-26 Hla class ii-restricted t cell receptors against ras with g12v mutation

Publications (1)

Publication Number Publication Date
BR112022016661A2 true BR112022016661A2 (pt) 2022-10-11

Family

ID=74885105

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016661A BR112022016661A2 (pt) 2020-02-26 2021-02-26 Receptores de células t restritos ao hla classe ii contra ras com mutação g12v

Country Status (12)

Country Link
US (1) US20230159614A1 (enExample)
EP (1) EP4110804A1 (enExample)
JP (1) JP7742354B2 (enExample)
KR (1) KR20220143939A (enExample)
CN (1) CN115244075A (enExample)
AU (1) AU2021225872A1 (enExample)
BR (1) BR112022016661A2 (enExample)
CA (1) CA3169086A1 (enExample)
GB (1) GB2610069B (enExample)
MX (1) MX2022010157A (enExample)
TW (1) TWI900533B (enExample)
WO (1) WO2021173902A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240000834A1 (en) * 2020-11-24 2024-01-04 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
KR20250037592A (ko) 2017-09-20 2025-03-17 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
CR20200287A (es) * 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
WO2019129892A1 (en) * 2017-12-29 2019-07-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof
GB201804724D0 (en) * 2018-03-23 2018-05-09 Univ Oslo Hf Method of diagnosing cceliac disease
WO2019231326A1 (en) * 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof
WO2022183167A1 (en) * 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof

Also Published As

Publication number Publication date
CN115244075A (zh) 2022-10-25
EP4110804A1 (en) 2023-01-04
KR20220143939A (ko) 2022-10-25
AU2021225872A1 (en) 2022-09-15
GB2610069A (en) 2023-02-22
GB2610069B (en) 2025-04-16
US20230159614A1 (en) 2023-05-25
TWI900533B (zh) 2025-10-11
JP7742354B2 (ja) 2025-09-19
WO2021173902A1 (en) 2021-09-02
GB202212195D0 (en) 2022-10-05
CA3169086A1 (en) 2021-09-02
MX2022010157A (es) 2022-10-18
TW202140537A (zh) 2021-11-01
JP2023527613A (ja) 2023-06-30

Similar Documents

Publication Publication Date Title
BR112022016661A2 (pt) Receptores de células t restritos ao hla classe ii contra ras com mutação g12v
BR112022015888A2 (pt) Receptores de células t restritos a hla classe i contra ras com mutação g12d
BR112021026408A2 (pt) Receptores de célula t que reconhecem a mutação r175h ou y220c em p53
BR112022015897A2 (pt) Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
Clatworthy et al. Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes
EP3301107B1 (en) Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment
EA202090652A1 (ru) T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras
BR112022001923A2 (pt) Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno
Testa et al. MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response
CA3066635A1 (en) Neoantigen identification, manufacture, and use
CR20250153A (es) RECEPTORES DE CÉLULAS T QUE RECONOCEN P53 MUTADO (Divisional Expediente 2020-0170)
González et al. Synthesis, LC-MS/MS analysis, and biological evaluation of two vaccine candidates against ticks based on the antigenic P0 peptide from R. sanguineus linked to the p64K carrier protein from Neisseria meningitidis
BR112023001815A2 (pt) Peptídeo, anticorpo, receptor de célula t, ácido nucleico, célula hospedeira recombinante, método in vitro para produzir linfócitos t ativados, linfócito t ativado, composição farmacêutica, e, kit
EP4241274A1 (en) Selecting neoantigens for personalized cancer vaccine
Gutiérrez-Sánchez et al. Two MP2CL5 antigen vaccines from Naegleria fowleri stimulate the immune response against meningitis in the BALB/c model
Li et al. GILT in tumor cells improves T cell-mediated anti-tumor immune surveillance
Katsuhara et al. Transduction of a novel HLA-DRB1* 04: 05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells
CN120904299B (zh) 一种猴痘病毒抗原表位肽及其应用
BR112023005296A2 (pt) Receptores de células t específicos de mage-a3 e uso dos mesmos
KR20230071527A (ko) 에피토프 기반 치료 백신 설계용 플랫폼 기술
y García et al. C5aR contributes to the weak Th1 profile induced by an outbreak strain of Mycobacterium tuberculosis
Ayyoub et al. Distinct but overlapping T helper epitopes in the 37–58 region of SSX-2
Pandey et al. Retracted: Evaluating the immunomodulatory responses of LdODC‐derived MHC Class‐II restricted peptides against VL
Nagamata et al. Identification of CD4 and H-2Kd-restricted cytotoxic T lymphocyte epitopes on the human herpesvirus 6B glycoprotein Q1 protein